Quarterly report · Q2
2160.TEDINET S100ROIG
Period2023-01-01 → 2023-06-30
Filed2023-08-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥14.1bn | 2023-01-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥9.9bn | 2023-04-01 → 2023-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥17.4bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥8.2bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.2bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥5.5bn | 2023-01-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥5.1bn | 2023-04-01 → 2023-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.0bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥526m | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥5.1bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥5.2bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥768m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥790m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥443m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.7bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥389m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥676m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥325m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.0bn | 2023-01-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥4.4bn | 2023-04-01 → 2023-06-30d | Cons. | Profit loss IFRS |
| Net income | −¥868m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥198m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥126m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥45.1bn | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥33.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥35.3bn | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥20.3bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥14.1bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥24.8bn | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥21.8bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥23.0bn | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥22.0bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥14.1bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥872m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥393m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥389m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥2.6bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥4.1bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.5bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥3.9bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥646m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥267m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥34.93 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥34.99 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥14.25 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥6.86 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥34.81 | 2023-01-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥34.88 | 2023-04-01 → 2023-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.11 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥14.18 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥6.83 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 51.0% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.8% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-06-30 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-06-30 | −¥23m |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥1.4bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥1.3bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥23m |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥512m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥5.0bn |
| —segment total | revenue | 2023-01-01 → 2023-06-30 | ¥14.1bn |
| —segment total | revenue external | 2023-01-01 → 2023-06-30 | ¥14.1bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-06-30 | ¥23m |
| —segment total | segment profit | 2023-01-01 → 2023-06-30 | ¥5.5bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥526m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥479m |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥8.2bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥8.2bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 670
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YTDDuration | -267292000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | CurrentYTDDuration | 3942881000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | -646327000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1QuarterInstant | 14466828000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | CurrentQuarterInstant | 14076753000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 11049310000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 47487843 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 47487843 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 47487843 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 47487843 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 1749100 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.0368 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1447712 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0305 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1376594 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0290 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 1000000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0211 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 386424 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0081 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 373611 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0079 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 372394 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0078 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 370600 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0078 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 256394 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0054 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 247400 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0052 | |
| Number of shares held | CurrentQuarterInstant | 7580229 | |
| Shareholding ratio | CurrentQuarterInstant | 0.1596 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1400 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 47470800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 474708 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 15643 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 47487843 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 474708 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 1400 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 1400 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 1400 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 1400 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0000 | |
| Property plant and equipment IFRS | Prior1YearInstant | 3951217000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |